FindTrial
Sign In

study of drug interferon injected through lumbar puncture in ptients of life threatening illness,Subacute Sclerosing Panencephalitis

Intrathecal interferon alpha in Subacute Sclerosing Panencephalitis patients

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2009/091/000937
Enrollment
Unknown
Registered
2009-12-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Intrathecal interferon: 6 MIU weekly for 6 months and then monthly for next six months Control Intervention1: Oral symptomatic drugs:

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients fullfilling Dykens criteria for SSPE

Exclusion criteria

Exclusion criteria: Advanced illness(Stage 4 of jabbours staging)

Design outcomes

Primary

MeasureTime frame
Modified rankin score and Jabbours stageTimepoint: At enrollment and at 8th month—

Secondary

MeasureTime frame
DeathTimepoint: At the end of 8 months—

Countries

India

Contacts

Public ContactProf R K Garg
garg50@yahoo.com09335901790

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026